No Data
No Data
No Data
No Data
No Data
Janux a New Buy at Jones on Lead Assets for Solid Tumors
Seeking AlphaApr 16 14:25 ET
A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts
In the latest quarter, 6 analysts provided ratings for Janux Therapeutics (NASDAQ:JANX), showcasing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the table below illu
BenzingaApr 16 08:00 ET
Express News | JonesTrading Initiates Coverage On Janux Therapeutics With Buy Rating, Announces Price Target of $70
Moomoo 24/7Apr 16 06:50 ET
Janux Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 34.98% JonesTrading → $70 Initiates Coverage On → Buy 03/21/2024 19.55% BTIG → $62 Initiates Co
BenzingaApr 16 06:49 ET
Express News | Janux Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $70
Moomoo 24/7Apr 16 00:44 ET
Buy Rating Affirmed for Janux Therapeutics on Innovative Oncology Treatments and M&A Potential
TipRanksApr 15 16:15 ET
No Data
No Data